CA03879J1003
CA03879J1003
Arbutus Biopharma Corporation
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 646.82M EUR | 948.64M EUR | 886.26M EUR | 926.08M EUR |
Enterprise Value | 738M EUR | 929.99M EUR | 863.19M EUR | 908.81M EUR |
Valuation Multiples | ||||
Trailing P/E | 5.34x | 6.2x | 5.51x | -- |
Forward P/E | -25.53x | -- | -- | -- |
Price to Sales | 3.56x | 5.22x | 4.63x | 75.17x |
Price to Book | 3.22x | 3.67x | 3.41x | 12.09x |
EV/Revenue | 4.06x | 5.12x | 4.51x | 73.77x |
EV/EBITDA | 5x | 6.16x | 5.43x | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -12.4% | -2.6% | -3.88% | -2.83% |